Trial | NCT00442806  Report issue

Title

Randomized Clinical Trial of Adipose-Derived Stem Cells in the Treatment of Pts With ST-elevation Myocardial Infarction
A Randomized Clinical Trial of AdiPOse-derived Stem ceLLs in the Treatment of Patients With ST-elevation myOcardial Infarction - The APOLLO Trial

  • Phase

    Phase 1

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    14
The purpose of this study is to establish safety and feasibility of utilizing Adipose-Derived Stem and Regenerative Cells (ADRC's) in patients who have suffered a ST-elevation acute myocardial infarction.
Subjects who have coronary artery disease and have suffered a ST-elevation acute myocardial infarction will be evaluated for eligibility in this study. Eligible subjects will undergo standard treatment after admission to the hospital and will then undergo liposuction under local anesthesia, after which ADRC's will be isolated from the lipoaspirate. According to randomization subjects will receive either ADRC's or placebo.
Study Started
Nov 30
2007
Primary Completion
Apr 30
2012
Study Completion
Apr 30
2012
Last Update
Nov 26
2013
Estimate

Drug Injection of ADRC's

ADRC's are injected

Other Injection of Placebo

Placebo is injected

Placebo Placebo Comparator

Placebo is injected

Treatment Experimental

ADRC's are injected

Criteria 

Key Inclusion Criteria:

Acute myocardial infarction (AMI)
Clinical symptoms consistent with AMI for a minimum of 2 and a maximum of 12 hours from onset of symptoms to Percutaneous Coronary Intervention (PCI), and unresponsive to nitroglycerin
Successful revascularization of the culprit lesion in the major epicardial vessel
Area of hypo- or akinesia corresponding to the culprit lesion, as determined by left ventriculogram at the time of primary PCI
Left ventricular ejection fraction (LVEF) ≥30% and ≤50% by Left Ventricular Angiography at the time of successful revascularization.
Ability to undergo liposuction

Key Exclusion Criteria:

Prior MI, prior known cardiomyopathy, or prior hospital admission for congestive heart failure (CHF)
More than 24 hours after acute PCI
Significant valvular disease
More than twelve hours between the onset of first symptoms of AMI and revascularization
Hemodynamic instability within 24 hours prior to randomization
Neoplasia
Acute or chronic bacterial or viral infectious disease
Pacemaker, ICD or any other contra-indication for MRI
LVEF <30% or >50% by Left Ventricular Angiography
Moderate or severe COPD
No Results Posted